Table 1.
Effect of DMS on vasomotor responses to 5-HT, S1P and PE in basilar and femoral arteries of rat: pharmacological parameters.
| pD2 | EC50 (µmol/L) | Emax (% K+) | |
|---|---|---|---|
| 5-HT | |||
| Basilar | |||
| Control | 7.18 ± 0.09 | 0.07 (0.04–0.10) | 100.3 ± 3.2 |
| DMS 5 µmol/L | 6.64 ± 0.22 | 0.22 (0.08–0.64) | 73.9 ± 6.6** |
| DMS 10 µmol/L | 6.68 ± 0.39 | 0.21 (0.03–1.26) | 64.0 ± 10.0** |
| DMS 20 µmol/L | 6.11 ± 0.13** | 0.77 (0.43–1.40) | 69.0 ± 4.9** |
| Femoral | |||
| Control | 6.44 ± 0.11 | 0.36 (0.22–0.60) | 111.4 ± 8.3 |
| DMS 5 µmol/L | 6.56 ± 0.11 | 0.27 (0.17–0.46) | 117.2 ± 8.2 |
| DMS 10 µmol/L | 6.45 ± 0.08 | 0.36 (0.24–0.52) | 124.1 ± 7.1 |
| DMS 20 µmol/L | 6.52 ± 0.10 | 0.30 (0.19–0.48) | 115.9 ± 7.3 |
| S1P | |||
| Basilar | |||
| Control | 6.03 ± 0.11 | 0.94 (0.57–1.55) | 80.7 ± 3.3 |
| DMS 5 µmol/L | 6.14 ± 0.26 | 0.73 (0.21–2.47) | 57.8 ± 5.6** |
| DMS 10 µmol/L | 6.44 ± 0.60 | 0.36 (0.02–5.97) | 35.4 ± 7.5** |
| DMS 20 µmol/L | 5.30 ± 0.72 | 5.04 (0.18–1000) | 4.8 ± 2.0** |
| PE | |||
| Femoral | |||
| Control | 5.32 ± 0.13 | 4.77 (2.59–8.77) | 88.8 ± 6.3 |
| DMS 5 µmol/L | 5.35 ± 0.11 | 4.50 (2.70–7.53) | 89.5 ± 5.3 |
| DMS 10 µmol/L | 5.32 ± 0.11 | 4.78 (2.90–7.89) | 85.7 ± 5.0 |
| DMS 20 µmol/L | 5.63 ± 0.11 | 2.37 (1.40–4.02) | 91.0 ± 5.0 |
Pharmacological parameters are from non linear regression; pD2 is the negative logarithm of the concentration producing 50% of the maximum effect, EC50 is the concentration producing 50% of the maximum effect (95% confidence limits are given in parenthesis), Emax is the maximum effect (in % of vasoconstriction evoked in the same preparations by 100 mmol/L K+).
Data are mean ± SEM of 5–12 independent measurements. Statistical comparisons were made on the whole curves by two-way ANOVA;
**
P<0.01 versus Control.